stockrow
Friday 6 November 2026
Export GMAB’s income statement to Excel — free account
Genmab A/S Sponsored ADR
GMAB Healthcare Biotechnology
Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024.
- Revenue
- +24.9%
- EPS
- −9.26%
- Free cash flow
- −7.69%
Quarter to June 2026, against a year earlier
53.58
0.84
+1.59%
Follow GMAB
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
13.00 | 19.87 | 20.33 | 21.63 |
P/S ratio |
5.27 | 5.15 | 4.34 | 4.08 | |
P/FCF ratio |
15.89 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
35.25 | 63.60 | 5,642.80 | 330.37 | |
P/B ratio |
3.29 | 3.27 | 2.98 | 2.83 | |
Price to Tangible BV |
5.18 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
4.35 | 6.10 | 5.28 | 4.96 | |
EV/EBITDA |
11.27 | 19.98 | 18.07 | 17.57 | |
EV/Operating CF |
12.24 | 19.14 | 22.86 | 22.99 | |
EV/FCF |
13.12 | (3.73) | (3.24) | (3.23) | |
Quick Ratio |
6.01 | 2.01 | 2.17 | 2.44 | |
Current Ratio |
6.03 | 2.02 | 2.18 | 2.46 | |
Net Debt/EBITDA |
(7.15) | 45.05 | 17.64 | 9.06 | |
Debt/Assets |
0.00% | 40.97% | 42.08% | 41.03% | |
Debt/Equity |
0.00 | 0.90 | 0.92 | 0.86 | |
Asset Turnover |
0.56 | 0.39 | 0.41 | 0.44 | |
Operating CF/Net income |
1.34 | 9.71 | 0.06 | 0.17 | |
Capex/Depreciation |
(0.11) | (344.19) | (0.17) | (0.12) | |
Interest Coverage |
12.41 | 0.60 | 1.20 | 2.70 | |
Research and Development Expense of Revenue |
34.93% | 49.72% | 49.11% | 39.74% | |
Selling, General and Administrative Expense of Revenue |
14.48% | 19.66% | 18.53% | 17.75% | |
Intangible Assets out of Total Assets |
0.30 | 0.74 | 0.75 | 0.74 | |
Share Based Compensation of Revenue |
3.33% | 3.40% | 5.47% | 3.20% | |
Graham Net Nets |
0.17 | (0.22) | (0.24) | (0.22) | |
Graham Number |
22.27 | 18.11 | 16.35 | 16.66 | |
Earnings Yield |
7.69% | 5.03% | 4.92% | 4.62% | |
Free Cash Flow Yield |
6.29% | (31.78%) | (37.58%) | (37.67%) | |
Revenue per Share |
1.66 | 1.70 | 1.42 | 1.88 | |
Operating CF per Share |
0.87 | 0.48 | 0.00 | 0.08 | |
Capex per Share |
0.00 | (11.63) | (0.01) | 0.00 | |
Free Cash Flow per Share |
0.87 | (11.15) | 0.00 | 0.08 | |
Cash per Share |
5.54 | 2.76 | 2.41 | 2.45 | |
Shareholders Equity per Share |
9.34 | 9.41 | 9.01 | 9.71 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
9.34 | 9.41 | 9.01 | 9.71 | |
Free Cash Flow |
534.00 | (6,927.00) | (2.00) | 48.00 | |
Working Capital |
3,730.00 | 1,458.00 | 1,395.00 | 1,661.00 | |
Capital Expenditures |
(2.00) | (7,228.00) | (5.00) | (3.00) | |
Net Current Asset Value |
3,201.00 | (4,141.00) | (4,121.00) | (3,757.00) | |
EV/EBIT |
11.84 | 21.32 | 19.50 | 19.11 | |
Capex to Sales |
0.00 | 6.83 | 0.01 | 0.00 | |
Price to Operating Income |
14.34 | 17.97 | 16.02 | 15.72 | |
| Other line items | |||||
Average Receivables |
988.05 | 1,044.50 | 915.00 | 1,139.00 | |
Average Inventory |
12.23 | 13.50 | 16.50 | 15.50 | |
Average Assets |
6,433.44 | 9,643.50 | 9,481.00 | 9,489.50 | |
Average Common Equity |
5,228.15 | 5,492.00 | 5,489.00 | 5,629.50 |
Columns are period end dates · fundamentals updated 26 Oct 2026